11/18
08:07 am
sgmt
Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024 [Yahoo! Finance]
Medium
Report
Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024 [Yahoo! Finance]
11/18
08:00 am
sgmt
Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024
Medium
Report
Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024
11/15
03:26 pm
sgmt
Sagimet Biosciences Inc. (NASDAQ: SGMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
Low
Report
Sagimet Biosciences Inc. (NASDAQ: SGMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
11/14
08:12 am
sgmt
Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates [Yahoo! Finance]
High
Report
Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates [Yahoo! Finance]
11/14
08:00 am
sgmt
Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
High
Report
Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
11/12
08:19 am
sgmt
Sagimet Biosciences Inc. (NASDAQ: SGMT) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $12.00 price target on the stock.
Low
Report
Sagimet Biosciences Inc. (NASDAQ: SGMT) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $12.00 price target on the stock.
11/12
06:30 am
sgmt
Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne
Medium
Report
Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne
11/12
06:30 am
sgmt
Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne
Medium
Report
Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne
11/7
07:30 am
sgmt
Sagimet Biosciences to Participate in the UBS Global Healthcare Conference
Low
Report
Sagimet Biosciences to Participate in the UBS Global Healthcare Conference
10/31
08:35 am
sgmt
Sagimet Biosciences Inc. (NASDAQ: SGMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
Medium
Report
Sagimet Biosciences Inc. (NASDAQ: SGMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
10/29
07:00 am
sgmt
Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions with FDA on the Development of Denifanstat for MASH; Phase 3 Program Initiation Expected by End of 2024
Low
Report
Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions with FDA on the Development of Denifanstat for MASH; Phase 3 Program Initiation Expected by End of 2024
10/18
03:11 pm
sgmt
Sagimet Soars: FDA Breakthrough Therapy Designation And Lancet Review Validate Denifanstat [Seeking Alpha]
Low
Report
Sagimet Soars: FDA Breakthrough Therapy Designation And Lancet Review Validate Denifanstat [Seeking Alpha]
10/16
07:00 am
sgmt
Sagimet Biosciences Announces Upcoming Presentations at AASLD - The Liver Meeting® 2024
Medium
Report
Sagimet Biosciences Announces Upcoming Presentations at AASLD - The Liver Meeting® 2024
10/11
07:00 am
sgmt
Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology
Medium
Report
Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology
10/2
08:08 am
sgmt
Sagimet Biosciences Inc. (NASDAQ: SGMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
Medium
Report
Sagimet Biosciences Inc. (NASDAQ: SGMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
10/1
09:06 am
sgmt
Sagimet soars on FDA breakthrough therapy designation for its liver disease treatment [Seeking Alpha]
High
Report
Sagimet soars on FDA breakthrough therapy designation for its liver disease treatment [Seeking Alpha]
10/1
07:00 am
sgmt
Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH
High
Report
Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH
10/1
12:09 am
sgmt
Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
High
Report
Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
10/1
12:05 am
sgmt
Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
High
Report
Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
9/12
07:30 am
sgmt
Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit
Medium
Report
Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit
9/4
08:00 am
sgmt
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
Medium
Report
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences